2010 Biotechnology Research Review

Report Highlights

• Global sales of chiral technology products in 2008 were $4.3 billion and with 3.3% growth, the sales reached $4.5 billion in 2009. This market is expected to rise at a compound annual growth rate (CAGR) of 2.8% and reach $5.1 billion by 2014. The  chiral technology market is led by chiral synthesis products with more than 80% share.
  BCC Research report, Chiral Technology: Global Markets
  
• The market for innovative biological therapies in cancer treatment will nearly double in the next 5 years, eventually exceeding $50 billion in the next 5 to 10 years. The biotherapy segment has recorded a 34.1% annual growth rate since 2004, and is forecast to almost double by 2014. Recent analysis reveals that biologic drugs will account for about 50% of the top 100 drugs in 2014.
  BCC Research report, Biological Therapies for Cancer: Technologies and Global Markets
  
• A period of dynamic growth in the therapeutic vaccines market is expected with the rollout of some eight products before 2015, not only to treat cancer but to address nicotine addiction as well. The total worldwide market for therapeutic vaccines is expected to reach $137 million in 2010.  With increased product introductions, this market is expected to reach nearly $3.1 billion in 2014, a compound annual growth rate (CAGR) of more than 117%.
  BCC Research report, Therapeutic Vaccines: The Global Market

2010 BIOTECHNOLOGY RESEARCH REVIEW

Foreword

Several significant developments have aided and accelerated development and growth of markets for biotechnology.

The release of $21.5 billion from the 2009 American Recovery and Reinvestment Act (ARRA) for science and research directly fueled an increase in optimism and activity for the sector. Francis Collins, the first National Institutes of Health (NIH) director with a genomics background, presided over the reversal of President Bush’s ban on federal funds for embryonic stem cell research, and the NIH guidelines for future funding, followed by research guidelines themselves.

Biosimilar legislation also will have a long-term impact. Merck & Co set up a biosimilar-specific division, and the generic drug giant, Teva, plowed resources into this area. One of the most intriguing highlights, however, was the American Civil Liberties Union (ACLU) and the Public Patent Foundation (PUBPAT) case against Myriad Genetics over the Brac1 gene. Myriad lost and the consequences might affect many biotechnology products.

Orphan drug activity drew attention with Pfizer inaugurating its own division, while Genzyme had problems related to its Gaucher treatment (cerezyme) production. Other trends include cancer vaccines, direct-to-consumer genetic testing, and the human microbiome project.

This Biotechnology Research Review provides a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision-making since BCC Research was founded in 1971. It includes highlights of reports published in 2010 on the following biotechnology markets:

• Epigenomics: Opportunities in Biomarkers, Diagnostics and Therapeutics
• Global Biochip Markets: Microarrays and Lab-on-a-Chip
• Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
• New Developments in Treating Genetic Disorders: The Global Market
• Chiral Technology: Global Markets
• Therapeutic Vaccines: The Global Market
• Biological Therapies for Cancer: Technologies and Global Markets
• DNA Sequencing: Emerging Technologies and Applications

We hope you find this Research Review valuable, and we look forward to serving our customers’ biotechnology market research needs.